Literature DB >> 32222069

Risk of hospitalization and death due to infection in people with psoriasis: a population-based cohort study using the Clinical Practice Research Datalink.

Z Z N Yiu1, R Parisi2, M Lunt3, R B Warren1, C E M Griffiths1, S M Langan4,5, D M Ashcroft6.   

Abstract

BACKGROUND: Psoriasis is associated with risk factors for serious infections, but the independent relationship between psoriasis and serious infection is as yet unclear.
OBJECTIVES: To determine whether people with psoriasis have a higher risk of hospitalization due to any infection, respiratory infections, soft-tissue and skin infections, or a higher risk of death due to infection.
METHODS: We conducted a cohort study of people (≥ 18 years) with psoriasis using the UK Clinical Practice Research Datalink (CPRD GOLD) linked to Hospital Episode Statistics (HES) and Office for National Statistics (ONS) mortality records between 1 April 2003 and 31 December 2016, and matched with up to six comparators on age, sex and general practice. Hospitalization was ascertained from HES records; death was ascertained from ONS mortality records. Stratified Cox proportional hazard models were estimated, with stepwise adjustment in different models for potential confounders or mediators between psoriasis and serious infection.
RESULTS: There were 69 315 people with psoriasis and 338 620 comparators who were followed up for a median (interquartile range) of 4·9 (5·9) and 5·1 (6·3) years, respectively. People with psoriasis had a higher incidence rate of serious infection [20·5 per 1000 person-years, 95% confidence interval (CI) 20·0-21·0, n = 7631] compared with those without psoriasis (16·1 per 1000 person-years, 95% CI 15·9-16·3, n = 30 761). The fully adjusted hazard ratio for the association between psoriasis and serious infection was 1·36 (95% CI 1·31-1·40), with similar results across the other outcomes.
CONCLUSIONS: Psoriasis is associated with a small increase in the risk of serious infection. Further research is needed to understand how psoriasis predisposes to a higher risk of infection.
© 2020 The Authors. British Journal of Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.

Entities:  

Mesh:

Year:  2020        PMID: 32222069     DOI: 10.1111/bjd.19052

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  13 in total

Review 1.  Epidemiology of Psoriasis and Comorbid Diseases: A Narrative Review.

Authors:  Jin Bu; Ruilian Ding; Liangjia Zhou; Xiangming Chen; Erxia Shen
Journal:  Front Immunol       Date:  2022-06-10       Impact factor: 8.786

2.  Concordance and timing in recording cancer events in primary care, hospital and mortality records for patients with and without psoriasis: A population-based cohort study.

Authors:  Alex M Trafford; Rosa Parisi; Martin K Rutter; Evangelos Kontopantelis; Christopher E M Griffiths; Darren M Ashcroft
Journal:  PLoS One       Date:  2021-07-19       Impact factor: 3.240

3.  Associations between COVID-19 and skin conditions identified through epidemiology and genomic studies.

Authors:  Matthew T Patrick; Haihan Zhang; Rachael Wasikowski; Errol P Prens; Stephan Weidinger; Johann E Gudjonsson; James T Elder; Kevin He; Lam C Tsoi
Journal:  J Allergy Clin Immunol       Date:  2021-01-21       Impact factor: 14.290

4.  Furin Expression in Patients With Psoriasis-A Patient Cohort Endangered to SARS-COV2?

Authors:  Thomas Graier; Nicole Golob-Schwarzl; Wolfgang Weger; Theresa Benezeder; Clemens Painsi; Wolfgang Salmhofer; Peter Wolf
Journal:  Front Med (Lausanne)       Date:  2021-02-10

5.  COVID-19 vaccination intention among patients with psoriasis compared with immunosuppressed patients with other skin diseases and factors influencing their decision.

Authors:  E Sotiriou; K Bakirtzi; I Papadimitriou; E Paschou; E Vakirlis; A Lallas; D Ioannides
Journal:  Br J Dermatol       Date:  2021-04-18       Impact factor: 11.113

6.  Perception of the threat, mental health burden, and healthcare-seeking behavior change among psoriasis patients during the COVID-19 pandemic.

Authors:  Hsien-Yi Chiu; Nien-Feng Chang Liao; Yu Lin; Yu-Huei Huang
Journal:  PLoS One       Date:  2021-12-09       Impact factor: 3.240

7.  Comment on "Antipsoriatic treatments during COVID-19 outbreak".

Authors:  Ayman Abdelmaksoud; Mohamad Goldust; Michelangelo Vestita
Journal:  Dermatol Ther       Date:  2020-06-12       Impact factor: 3.858

8.  Factors associated with adverse COVID-19 outcomes in patients with psoriasis-insights from a global registry-based study.

Authors:  Satveer K Mahil; Nick Dand; Kayleigh J Mason; Zenas Z N Yiu; Teresa Tsakok; Freya Meynell; Bola Coker; Helen McAteer; Lucy Moorhead; Teena Mackenzie; Maria Teresa Rossi; Raquel Rivera; Emmanuel Mahe; Andrea Carugno; Michela Magnano; Giulia Rech; Esther A Balogh; Steven R Feldman; Claudia De La Cruz; Siew Eng Choon; Luigi Naldi; Jo Lambert; Phyllis Spuls; Denis Jullien; Hervé Bachelez; Devon E McMahon; Esther E Freeman; Paolo Gisondi; Luis Puig; Richard B Warren; Paola Di Meglio; Sinéad M Langan; Francesca Capon; Christopher E M Griffiths; Jonathan N Barker; Catherine H Smith
Journal:  J Allergy Clin Immunol       Date:  2020-10-16       Impact factor: 10.793

Review 9.  Biologics for Psoriasis during the COVID-19 Pandemic.

Authors:  Koji Kamiya; Mayumi Komine; Mamitaro Ohtsuki
Journal:  J Clin Med       Date:  2021-03-30       Impact factor: 4.241

10.  Risk of infections in psoriasis. A lesson to learn during the SARS-CoV-2 pandemic.

Authors:  L Naldi
Journal:  Br J Dermatol       Date:  2020-06-15       Impact factor: 11.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.